Seer Wins Key Patent Battle Against Bruker Subsidiaries
Event summary
- The Patent Trial and Appeal Board (PTAB) upheld 23 claims of Seer’s ’360 Patent on March 23, 2026, including five challenged claims.
- The patent covers methods for analyzing biological samples using engineered nano- and microparticles, critical to Seer’s Proteograph platform.
- Bruker subsidiaries PreOmics GmbH and Biognosys AG challenged 11 of 29 claims but failed to invalidate them.
- Seer’s intellectual property portfolio includes over 240 issued patents and pending applications worldwide.
The big picture
Seer’s victory in this patent dispute reinforces its leadership in deep proteomics, a field increasingly critical for drug discovery and precision medicine. The decision underscores the strategic value of Seer’s IP portfolio, which could deter competitors and attract partners in a rapidly evolving biotech landscape. The outcome also highlights the growing importance of patent protection in scaling proteomic technologies.
What we're watching
- IP Defense Strategy
- How Seer will leverage this victory to deter future challenges and solidify its market position.
- Competitive Response
- Whether Bruker or other competitors will escalate legal or technological countermeasures.
- Commercialization Pace
- The pace at which Seer can translate its protected IP into revenue growth and market expansion.
Related topics